Literature DB >> 12954137

Recurrent herpes simplex labialis: selected therapeutic options.

G Wayne Raborn1, Michael G A Grace.   

Abstract

Recurrent infection with herpes simplex virus 1 (HSV1), called herpes simplex labialis (HSL), is a global problem for patients with normal immune systems. An effective management program is needed for those with frequent HSL recurrences, particularly if associated morbidity and life-threatening factors are present and the patient's immune status is altered. Over the past 20 years, a variety of antiviral compounds (acyclovir, penciclovir, famciclovir, valacyclovir) have been introduced that may reduce healing time, lesion size and associated pain. Classical lesions are preceded by a prodrome, but others appear without warning, which makes them more difficult to treat. Various methods of application (intravenous, oral, topical) are used, depending on whether the patient is experiencing recurrent HSL infection or erythema multiforme or is scheduled to undergo a dental procedure, a surgical procedure or a dermatological face peel (the latter being known triggers for recurrence). This article outlines preferred treatment (including drugs and their modes of application) for adults and children in each situation, which should assist practitioners wishing to use antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954137

Source DB:  PubMed          Journal:  J Can Dent Assoc        ISSN: 0709-8936            Impact factor:   1.316


  11 in total

Review 1.  Laser treatment of recurrent herpes labialis: a literature review.

Authors:  Carlos de Paula Eduardo; Ana Cecilia Corrêa Aranha; Alyne Simões; Marina Stella Bello-Silva; Karen Muller Ramalho; Marcella Esteves-Oliveira; Patrícia Moreira de Freitas; Juliana Marotti; Jan Tunér
Journal:  Lasers Med Sci       Date:  2013-04-13       Impact factor: 3.161

2.  Topical iontophoresis of valaciclovir hydrochloride improves cutaneous aciclovir delivery.

Authors:  Nada Abla; Aarti Naik; Richard H Guy; Yogeshvar N Kalia
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 3.  Autophagy interaction with herpes simplex virus type-1 infection.

Authors:  Douglas O'Connell; Chengyu Liang
Journal:  Autophagy       Date:  2016-03-02       Impact factor: 16.016

4.  The diagnosis and management of oral herpes simplex infection.

Authors:  Catalena Birek; Giuseppe Ficarra
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.663

5.  Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis.

Authors:  Nasira Arain; Sharath C V Paravastu; Mubashir A Arain
Journal:  BMC Infect Dis       Date:  2015-02-21       Impact factor: 3.090

6.  Herpes labialis and Nigerian dental health care providers: knowledge, attitudes, behaviors, and refusal to treat.

Authors:  Clement Chinedu Azodo; Agnes O Umoh
Journal:  BMC Health Serv Res       Date:  2015-09-15       Impact factor: 2.655

7.  Oxidative stress and cellular immunity in patients with recurrent aphthous ulcers.

Authors:  E Avci; Z Z Akarslan; H Erten; S Coskun-Cevher
Journal:  Braz J Med Biol Res       Date:  2014-05-02       Impact factor: 2.590

Review 8.  What the dental practitioner needs to know about pharmaco-therapeutic modalities of COVID-19 treatment: A review.

Authors:  Najla Dar-Odeh; Shadia Elsayed; Hamzah Babkair; Shaden Abu-Hammad; Nebras Althagafi; Rayan Bahabri; Yasmin Salah Eldeen; Wejdan Aljohani; Osama Abu-Hammad
Journal:  J Dent Sci       Date:  2020-11-19       Impact factor: 2.080

9.  Seroprovalence of herpes simplex1, 2 IgG antibodies in patients with beta thalassemia in a major tertiary care hospital located in Yazd, Iran.

Authors:  A Atefi; F Binesh; A Hashemi; A Atefi; Mm Aminorroaya
Journal:  Iran J Ped Hematol Oncol       Date:  2014-04-20

10.  Clinical Study on the Effectiveness of Three Products in the Treatment of Herpes Simplex Labialis.

Authors:  Hanna Boes; Vlasios Goulioumis; Anna Wechsler; Stefan Zimmer; Mozhgan Bizhang
Journal:  Sci Rep       Date:  2020-04-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.